Back
Arcutis Biotherapeutics Inc (ARQT)
BiotechnologyARQT · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$24.85
+0.32%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-0.13
ROE
-1.4%
Gross margin
90.9%
Debt/Equity
0.60x
Revenue growth
60.1%
Arcutis Biotherapeutics Inc — company intelligence
Earnings surprises
Q2 2026$0.11 vs $0.04 est+150.6%
Q1 2026$-0.09 vs $-0.08 est-7.4%
Q4 2025$0.13 vs $0.12 est+12.4%
Q3 2025$0.06 vs $-0.10 est+158.9%
Analyst consensus · 14 analysts
12 Buy2 Hold0 Sell
Updated Aug 22, 2026
Insider activity · 90 days
19 buys4 sellsnet +207,081 shares
Burnett Patrickother 6,700 · Aug 12, 2026
Burnett Patrickother 8,300 · Aug 11, 2026
Matsuda MasaruSell 1,230 · Aug 3, 2026
Recent SEC filings
4 — Insider transaction reportAug 21, 2026
4 — Insider transaction reportAug 19, 2026
4 — Insider transaction reportAug 13, 2026
Latest news
Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals — ChartMill · 1w ago
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs Strong Growth with a Timely Technical Setup — ChartMill · 2w ago
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38 — Benzinga · 2w ago
Arcutis Biotherapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation — SeekingAlpha · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.